Drugs being explicitly developed to treat rare diseases are getting more expensive. An analysis by Reuters found that prices ...

U.S. President Donald Trump's trade negotiators are pushing the EU to make unilateral tariff reductions on U.S. goods, saying ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid, data-driven breakthroughs. This hybrid approach is cutting costs, ...

President Donald Trump is right that Americans pay too much for many pharmaceuticals. However, his legally unenforceable ...

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, ...

BioCardia, Inc. ( NASDAQ: BCDA) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Joe Pantginis - H.C. Wainwright Laura ...

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

Dimerix and its kidney drug is on track but with results of its phase III trial not due for years, a few more twists and turns are likely.

Intrepid Labs, a biotechnology company transforming drug formulation development through the use of artificial intelligence (AI) and robotics, emerged from stealth today to accelerate therapeutics ...

A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce pharmaceutical development costs. Their work, published in the Journal of the ...